MARKET

ORKA

ORKA

Oruka Therapeutics Inc
NASDAQ
63.98
+0.80
+1.26%
Opening 15:48 05/14 EDT
OPEN
63.36
PREV CLOSE
63.18
HIGH
65.50
LOW
61.63
VOLUME
914.69K
TURNOVER
--
52 WEEK HIGH
91.00
52 WEEK LOW
8.91
MARKET CAP
3.83B
P/E (TTM)
-27.6780
1D
5D
1M
3M
1Y
5Y
1D
BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target
Benzinga · 8h ago
Julian Harrison Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target on Strong Clinical Profile and Cash Position
TipRanks · 9h ago
Barclays Remains a Buy on Oruka Therapeutics (ORKA)
TipRanks · 10h ago
Oruka Initiated With Buy on Best-in-Class ORKA-001 Psoriasis Data, Strong Cash Position, and Multi-Billion-Dollar Upside Potential
TipRanks · 21h ago
Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally
NASDAQ · 23h ago
Oruka Therapeutics GAAP EPS of -$0.48 beats by $0.07
Seeking Alpha · 23h ago
Oruka Therapeutics Q1 FY26 net loss widens 52% to $31.82 million
PUBT · 23h ago
Oruka's Psoriasis Data Already Priced In Unless the Quarterly Dosing Profile Surprises
Barchart · 2d ago
More
About ORKA
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).

Webull offers Oruka Therapeutics Inc stock information, including NASDAQ: ORKA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORKA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ORKA stock methods without spending real money on the virtual paper trading platform.